We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Spectral Begins Trading on OTCQX
News

Spectral Begins Trading on OTCQX

Spectral Begins Trading on OTCQX
News

Spectral Begins Trading on OTCQX

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Spectral Begins Trading on OTCQX"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Spectral Diagnostics Inc. has announced that its common shares have commenced trading on OTCQX International, the highest tier of the OTC market in the United States, under the symbol "DIAGF".

Spectral's common shares will continue to trade on the TSX under the symbol "SDI".

Spectral expects to benefit from trading on OTCQX by gaining greater exposure and liquidity in the United States, which represents the major market for its theranostic treatment, and where most of its Phase III EUPHRATES trial sites are located.

"We believe OTCQX will provide an expedient and transparent forum for investors in the United States, the world's largest equity market, to evaluate Spectral as a prospective investment and increase awareness of the Company's ongoing developments and progress," said Anthony Businskas, Executive Vice President and CFO of Spectral.

Brean Murray, Carret & Co. will act as the Company's Principal American Liaison (PAL) on OTCQX, and provide guidance on OTCQX requirements.

Advertisement